{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T05:17:17Z","timestamp":1649049437324},"reference-count":21,"publisher":"Informa UK Limited","issue":"14","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2020,12,5]]},"DOI":"10.1080\/10428194.2020.1837798","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T08:12:31Z","timestamp":1604477551000},"page":"3283-3286","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?"],"prefix":"10.1080","volume":"61","author":[{"given":"R. Andrew","family":"Harkins","sequence":"first","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department Chair, Department of Lymphoma\/Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq495"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0461-y"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.22.1.91"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0455"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00449-0"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00486-6"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-5050-9"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1808208"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"CIT0011","unstructured":"NICE. National Institute for Health and Care Excellence: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma 2020. [cited 2020]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta649\/documents\/final-appraisal-determination-document."},{"key":"CIT0012","unstructured":"NICE. National Institute for Health and Care Excellence: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (preliminary result) 2020. [cited 2020]. Available from: https:\/\/www.nice.org.uk\/guidance\/GID-TA10463\/documents\/129."},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2017.1330152"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3316"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00176-5"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-019-0916-3"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2019.1680288"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000411"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00564-1"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2518"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-518423"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2020.1837798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T06:12:49Z","timestamp":1645942369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2020.1837798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":21,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,12,5]]}},"alternative-id":["10.1080\/10428194.2020.1837798"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2020.1837798","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}